Immunologic Research

, Volume 49, Issue 1–3, pp 216–226 | Cite as

Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response

Article

Abstract

There is no approved therapy for food allergies, which affect 12 million people in the United States and millions more worldwide. In the last few years, our research team at Duke has begun to develop protocols to treat peanut and other food allergies. Two distinct therapies are being developed. Oral immunotherapy (OIT), which relies on ingestion of increasing amounts of the allergenic food, has been used to successfully desensitize more than 50 peanut allergic subjects. Sublingual immunotherapy (SLIT) involves placing small quantities of peanut allergens under the tongue and has shown promise in our initial placebo-controlled clinical trial. Immunologic changes associated with OIT and SLIT include reduction in mast cell reactivity as determined by skin prick test size, decreased basophil responses, decreased specific-IgE, increased IgG4, and induction of regulatory T cells. Development of these immunotherapy strategies has generated much excitement in the food allergy community; however, further studies are needed before these approaches are ready for clinical use.

Keywords

Food allergy Peanut allergy Oral immunotherapy Sublingual immunotherapy Desensitization Tolerance 

Notes

Acknowledgments

We would like to thank the subjects and their families for their dedication to the clinical studies at Duke. We would also like to thank the various funding agencies that made this research possible: National Institutes of Health, Food Allergy Initiative, Food Allergy and Anaphylaxis Network, Wallace Research Foundation, Thrasher Research Fund, and National Peanut Board.

References

  1. 1.
    Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008;121:1344–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol. 2005;115:3–12 [quiz 13].Google Scholar
  3. 3.
    Burks AW. Peanut allergy. Lancet. 2008;371:1538–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med. 2008.Google Scholar
  5. 5.
    Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;124:1549–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Ker J, Hartert TV. The atopic march: what’s the evidence? Ann Allergy Asthma Immunol. 2009;103:282–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Okada H, Kuhn C, Feillet H, Bach JF. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160:1–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee LA, Burks AW. Food allergies: prevalence, molecular characterization, and treatment/prevention strategies. Annu Rev Nutr. 2006;26:539–65.PubMedCrossRefGoogle Scholar
  9. 9.
    Moreno FJ, Clemente A. 2S albumin storage proteins: what makes them food allergens? Open Biochem J. 2008;2:16–28.PubMedGoogle Scholar
  10. 10.
    Breiteneder H, Radauer C. A classification of plant food allergens. J Allergy Clin Immunol. 2004;113:821–30 [quiz 831].Google Scholar
  11. 11.
    Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol. 2007;120:1413–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2007;120:1172–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Jarvinen KM, Beyer K, Vila L, Bardina L, Mishoe M, Sampson HA. Specificity of IgE antibodies to sequential epitopes of hen’s egg ovomucoid as a marker for persistence of egg allergy. Allergy. 2007;62:758–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. J Allergy Clin Immunol. 2001;107:367–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001–2006. J Allergy Clin Immunol. 2007;119:1016–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Yunginger JW, Squillace DL, Jones RT, Helm RM. Fatal anaphylactic reactions induced by peanuts. Allergy Proc. 1989;10:249–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor SL, Hefle SL, Bindslev-Jensen C, Bock SA, Burks AW Jr, Christie L, Hill DJ, Host A, Hourihane JO, Lack G, Metcalfe DD, Moneret-Vautrin DA, Vadas PA, Rance F, Skrypec DJ, Trautman TA, Yman IM, Zeiger RS. Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol. 2002;109:24–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Boyano-Martinez T, Garcia-Ara C, Pedrosa M, Diaz-Pena JM, Quirce S. Accidental allergic reactions in children allergic to cow’s milk proteins. J Allergy Clin Immunol. 2009;123:883–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Yu JW, Kagan R, Verreault N, Nicolas N, Joseph L, St Pierre Y, Clarke A. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol. 2006;118:466–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol. 1997;100:444–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, Steele PH, Pons L, Helm RM, Lee LA, Burks AW. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119:199–205.PubMedCrossRefGoogle Scholar
  25. 25.
    Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;119:780–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292–300 [300 e291–297].Google Scholar
  27. 27.
    Vickery B, Lin J, Kulis M, Steele P, Jones SM, Bardina L, Sampson H, Burks AW. Peanut oral immunotherapy (OIT) induces epitope-specific isotype shift from IgE to IgG4. J Allergy Clin Immunol. 2010;125:AB20.CrossRefGoogle Scholar
  28. 28.
    Shreffler WG, Wanich N, Moloney M, Nowak-Wegrzyn A, Sampson HA. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. J Allergy Clin Immunol. 2009;123:43–52 [e47].Google Scholar
  29. 29.
    Breslin M, Pons L, Yue X, Kulis M, Jones SM, Vickery B, Burks AW. Peanut oral immunotherapy (OIT) confers long-term tolerance mediated by decreased T-helper Type 2 (Th2) cytokines and cytokines generated by regulatory T cells (Tregs). J Allergy Clin Immunol. 2010;125:AB20.CrossRefGoogle Scholar
  30. 30.
    Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124:286–291 [291 e281–86].Google Scholar
  31. 31.
    Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, Perry TT, Jones SM, Burks AW. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124:1351–2.PubMedCrossRefGoogle Scholar
  32. 32.
    Jones SM, Scurlock AM, Pons L, Perry TT, Morgan AR, Kulis M, Vickery B, Steele P, Kamilaris J, Hiegel AM, Burks AW. Double-blind, placebo-controlled trial of oral immunotherapy (OIT) in peanut (PN) allergic children: a follow-up. J Allergy Clin Immunol. 2010;125:AB58.CrossRefGoogle Scholar
  33. 33.
    Varshney P, Jones SM, Pons L, Kulis M, Steele P, Kemper AR, Scurlock AM, Perry TT, Burks AW. Peanut oral immunotherapy (OIT) induces immunologic changes supporting the development of tolerance. J Allergy Clin Immunol. 2010;125:AB59.CrossRefGoogle Scholar
  34. 34.
    Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125:S116–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol. 2003;14:378–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Edie AH, Steele P, Kamilaris J, Stowe R, Dunn A, Chin W, Jones SM, Burks AW. Improvement of quality of life in children with peanut allergy upon development of tolerance to peanut. J Allergy Clin Immunol. 2010;125:AB52.CrossRefGoogle Scholar
  37. 37.
    Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009;64:1218–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, Shreffler WG, Sampson HA, Niggemann B, Wahn U, Beyer K. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126:83–91 [e81].Google Scholar
  39. 39.
    Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T, Dimova D, Dumitrascu D, Fontana L, Katelaris CH, Kaulsay R, Kuna P, Larenas-Linnemann D, Manoussakis M, Nekam K, Nunes C, O’Hehir R, Olaguibel JM, Onder NB, Park JW, Priftanji A, Puy R, Sarmiento L, Scadding G, Schmid-Grendelmeier P, Seberova E, Sepiashvili R, Sole D, Togias A, Tomino C, Toskala E, Van Beever H, Vieths S. Sub-lingual immunotherapy: world allergy organization position paper 2009. Allergy. 2009;64(Suppl 91):1–59.PubMedGoogle Scholar
  40. 40.
    Passalacqua G, Lombardi C, Troise C, Canonica GW. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol. 2009;41:163–70.PubMedGoogle Scholar
  41. 41.
    Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, Castello JV, Alonso R, de Mateo JA, Cerda-Trias T, San Miguel-Moncin Mdel M, Monzon S, Garcia M, Palacios R, Cistero-Bahima A. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Webber CM, England RW. Oral allergy syndrome: a clinical, diagnostic, and therapeutic challenge. Ann Allergy Asthma Immunol. 2010;104:101–08 [quiz 109–10, 17].Google Scholar
  43. 43.
    Kerzl R, Simonowa A, Ring J, Ollert M, Mempel M. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol. 2007;119:507–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE, Gonzalez-Mancebo E, Martin S, Barber D, Rico P, Tabar AI. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64:876–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Plosker GL, Keam SJ. Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs. 2008;22:189–204.PubMedCrossRefGoogle Scholar
  46. 46.
    Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Du Toit G, Katz Y, Sasieni P, Mesher D, Maleki SJ, Fisher HR, Fox AT, Turcanu V, Amir T, Zadik-Mnuhin G, Cohen A, Livne I, Lack G. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol. 2008;122:984–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Lopez-Exposito I, Song Y, Jarvinen KM, Srivastava K, Li XM. Maternal peanut exposure during pregnancy and lactation reduces peanut allergy risk in offspring. J Allergy Clin Immunol. 2009;124:1039–46.PubMedCrossRefGoogle Scholar
  49. 49.
    Sicherer SH, Wood RA, Stablein D, Burks AW, Liu AH, Jones SM, Fleischer DM, Leung DY, Grishin A, Mayer L, Shreffler W, Lindblad R, Sampson HA. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy. J Allergy Clin Immunol. 2010;125:1077–83 [e1078].Google Scholar
  50. 50.
    Li XM, Srivastava K, Grishin A, Huang CK, Schofield B, Burks W, Sampson HA. Persistent protective effect of heat-killed Escherichia coli producing “engineered”, recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol. 2003;112:159–67.PubMedCrossRefGoogle Scholar
  51. 51.
    Pochard P, Vickery B, Berin MC, Grishin A, Sampson HA, Caplan M, Bottomly K. Targeting Toll-like receptors on dendritic cells modifies the T(H)2 response to peanut allergens in vitro. J Allergy Clin Immunol. 2010;126:92–7 [e95].Google Scholar
  52. 52.
    Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122:1154–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L, Wallenstein S, Goldfarb J, Sampson HA, Li XM. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol. 2005;115:171–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Srivastava KD, Qu C, Zhang T, Goldfarb J, Sampson HA, Li XM. Food allergy herbal formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8 + T cells. J Allergy Clin Immunol. 2009;123:443–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Wang J, Patil SP, Yang N, Ko J, Lee J, Noone S, Sampson HA, Li XM. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol. 2010;105:75–84.PubMedCrossRefGoogle Scholar
  56. 56.
    Clark AT, Ewan PW. The development and progression of allergy to multiple nuts at different ages. Pediatr Allergy Immunol. 2005;16:507–11.PubMedCrossRefGoogle Scholar
  57. 57.
    Kulis M, Li Y, Pons L, Burks AW. Walnut immunotherapy (IT) as treatment for both cashew and walnut allergy. J Allergy Clin Immunol. 2009;123:S175.CrossRefGoogle Scholar
  58. 58.
    Thyagarajan A, Varshney P, Jones SM, Sicherer S, Wood R, Vickery BP, Sampson H, Burks AW. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol. 2010;126:31–2.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Mike Kulis
    • 1
  • Brian P. Vickery
    • 1
  • A. Wesley Burks
    • 1
  1. 1.Department of Pediatric Allergy and ImmunologyDuke University Medical CenterDurhamUSA

Personalised recommendations